Precision Neuroscience just picked up $250 million and a unicorn valuation for its brain implant.
The New York-based brain-computer interface startup announced the Series D round on September 24, 2026. Bill Ackman's Pershing Square Capital Management led the raise alongside the Ackman Oxman Institute and an unnamed life sciences fund. The deal values the company at just over $1 billion, according to a New York Times report. Precision did not disclose additional terms of the round.
Brain-computer interface funding used to be Neuralink's spotlight to lose. Now a rival is racing toward the same market with a very public financier behind it, and that matters more than the dollar figure: an activist investor known for corporate proxy fights, not biotech bets, putting his name on a neurotech round is a signal of how mainstream implant hardware has become to non-specialist money.
Valuations built on one unnamed backer and a still-experimental implant are easy to announce. The real test is whether Precision's hardware works outside a lab before the hype catches up with it.